 |
Home | Corporate Profile | Technology & Research | Investors | Contact Us |
A novel and dynamic biopharmaceutical company developing human therapies for neuroprotection and metabolic related disorders.
|
Neuren Pharmaceuticals Limited is a biopharmaceutical company developing drugs for brain injury and neurodegeneration. The drugs target acute indications of brain injury such as traumatic brain injury, as well as chronic conditions such as Parkinson’s and Alzheimer’s diseases. Neuren is also engaged in research and development in metabolic disorders such as cancers related to the functions of growth hormone. Neuren has three lead candidates; Motiva™ and NNZ-2566 presently in clinical development to treat three different neurological conditions, and NNZ-2591 in preclinical development for Parkinson’s disease dementia and other chronic neurodegenerative conditions. Neuren has operations in New Zealand (Auckland based head office), Australia and the United States, and is listed on the Australian Securities Exchange (ASX: NEU). |
|
Unsupported Listings: Neuren is aware of listings of securities on the Berlin Stock Exchange (code: NK9.BE) and in the US “Over the Counter” market (code: NURPF.PK). These securities have not been issued by Neuren and are not recorded in the Neuren share register. If you wish to trade in securities issued by Neuren you should ensure that they are acquired or sold through the Australian Securities Exchange (ASX code: NEU) which is the only listing supported by the Company.
Research Reports and News: NEW: Prepared by Bell Potter Securities Limited 17 October 2012 CEOCFO Magazine interview with Larry Glass 24 Sept 2012 Prepared by Bell Potter Securities Limited 7 Sept 2012 Prepared by Bell Potter Securities Limited 24 May 2012 |